Cargando…

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

PURPOSE: Glioblastoma multiforme (GBM) is resistant to current cytotoxic therapies, in part because of enhanced DNA repair. Activation of the receptor tyrosine kinase c-Met has been shown to protect cancer cells from DNA damage. We hypothesized that inhibiting c-Met would decrease this protection an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welsh, James W, Mahadevan, Daruka, Ellsworth, Ron, Cooke, Laurence, Bearss, David, Stea, Baldassarre
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806296/ https://www.ncbi.nlm.nih.gov/pubmed/20028557 http://dx.doi.org/10.1186/1748-717X-4-69

Ejemplares similares

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
por: Qi, Wenqing, et al.
Publicado: (2009)

Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients
por: Morrison, Christopher, et al.
Publicado: (2021)

Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme
por: Lickliter, Jason D., et al.
Publicado: (2023)

Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas
por: Lüttich, Lina, et al.
Publicado: (2021)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy
por: Islam, Shariful, et al.
Publicado: (2017)

The CFTR Met 470 Allele Is Associated with Lower Birth Rates in Fertile Men from a Population Isolate
por: Kosova, Gülüm, et al.
Publicado: (2010)

Amdahl 470 Chip Package
Publicado: (1975)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
por: Navis, Anna C., et al.
Publicado: (2013)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Aldaz, Paula, et al.
Publicado: (2021)

Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia.
por: Nishimura, Y., et al.
Publicado: (1996)

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2015)

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
por: Brooks, Colin, et al.
Publicado: (2012)

Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
por: Carrasco-García, Estefanía, et al.
Publicado: (2014)

Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer
por: Qi, Wenqing, et al.
Publicado: (2015)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Séminaire Bourbaki : exposés 453–470
por: Collective
Publicado: (1976)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

Radioresistance in Glioblastoma and the Development of Radiosensitizers
por: Ali, Md Yousuf, et al.
Publicado: (2020)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
por: Mekki, Meriem Sarah, et al.
Publicado: (2018)

Radiosensitizing effect of c-Met kinase inhibitor BPI-9016M in esophageal squamous cell carcinoma cells in vitro and in vivo
por: Jiang, Chenxue, et al.
Publicado: (2021)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
por: Tilak, Manali, et al.
Publicado: (2021)

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
por: Zhang, Yazhuo, et al.
Publicado: (2018)

Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase
por: Fernandes, Marie, et al.
Publicado: (2019)

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
por: Koo, Karen, et al.
Publicado: (2023)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

MON-470 Biotin Masquerading as Subclinical Hyperthyroidism
por: Eapen, Anita, et al.
Publicado: (2020)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6pmh84ves7d4c4se7m8vpm0kjp